Review on Toxicity of Antihypertensive Drugs
DOI:
https://doi.org/10.22270/ajdhs.v2i4.28Keywords:
Adverse drug reactions, Hypertension, hyperlipidemia, glucose metabolismAbstract
Adverse drug reactions are common and pose a serious health problem, limiting treatment options, causing compliance issues, and even leading to therapy discontinuation. Hypertension is a chronic disease that is regarded as a major risk factor for cardiovascular disease. To achieve a target blood pressure in an individual patient, a wide range of anti-hypertensive agents are available as single or combination therapy, whereas combination therapy increases the risk of developing Adverse Drug Reaction. Hypertensive patients frequently have coexisting disease conditions such as hyperlipidemia, impaired glucose metabolism, and renal impairment, which increase the risk of Cardio Vascular morbidity and mortality. When treating hypertensive patients, comprehensive management of both hypertension and concomitant Cardio Vascular Disease risk factors is essential. Some of the rare and serious Adverse Drug Reactions that occurred in patients treated with these drugs included beta-blockers causing psoriasis, calcium channel blockers causing gingival hyperplasia, peripheral oedema, Angiotensin Converting Enzyme inhibitors causing ankle oedema, and thiazide diuretics causing hyponatremia and hyperglycemia. Asymptomatic hypertension is more common and necessitates lifelong treatment with antihypertensive agents, predisposing to Adverse Drug Events.In order to improve treatment outcomes and reduce morbidity and mortality associated with adverse drug reactions, healthcare professionals must monitor adverse drug reactions in patients taking antihypertensive drugs.
Keywords: Adverse drug reactions, Hypertension, hyperlipidemia, glucose metabolism
References
Raghu Kumar V, Raghu Ram V, Guru Prasad B, Mohanta G.P and Manna P.K: A study of adverse drug reactions due to anti-hypertensive drugs in a tertiary care teaching hospital. International Journal of Pharmacy and Life Sciences 2011; 2:767-772.
Aellig HW: Adverse reactions to World Health Organisation preventing chronic diseases: a vital investment. Geneva, Switzerland: WHO; 2005.
Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997; 349: 1269-1276. https://doi.org/10.1016/S0140-6736(96)07493-4
Michel Joffres et al., Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. British Medical Journal 2013; 3:e003423. https://doi.org/10.1136/bmjopen-2013-003423
Peter Lloyd- Sherlock, John Beard, Nadia Minicuci, Shah Ebrahim and SomnathChatterji.:Hypertension among older adults in low-and middle-income countries: Prevalence, awareness and control. International Journal of Epidemiology 2014; 1-13. https://doi.org/10.1093/ije/dyt215
The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Archives of Internal Medicine 1997; 157:2413- 2446. https://doi.org/10.1001/archinte.1997.00440420033005
1999 World Health Organisation- International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines subcommittee.Journal of Hypertension 1999; 17:151-183. https://doi.org/10.1097/00004872-199917020-00001
Kaplan NM: Guidelines for the management of hypertension. Canadian Journal of Cardiology 2000; 16:1147-1152.
Ramsay L et al., Guidelines for the management of hypertension: Report of the third working party of the British hypertension society. Journal of Human Hypertension 1999; 13:569-592. https://doi.org/10.1038/sj.jhh.1000917
Scottish Intercollegiate Guidelines network. Hypertension in older people.A national clinical guideline. 2001. SIGN publication no. 49.
DabhadeSuhas, Bhosle Deepak, AtreKavita: Review on pharmacovigilance study of telmisartan in hypertension patients. Asian Journal of Pharmaceutical and Clinical Research 2013; 6:17-20.
Collins R, MacMahon S: Blood pressure, anti-hypertensive drug treatment and the risk of stroke and of coronary heart disease. British Medical Bulletin 1994; 50:272- 298. https://doi.org/10.1093/oxfordjournals.bmb.a072892
Neal B, Mac Mahon S and Chapman N: Effects of ACE inhibitors, Calcium antagonists and other blood pressurelowering drugs: results of prospectively designed overuse of randomised trials. Blood pressure lowering treatment trialists' Collaboration. Lancet 2000; 355:1955-1964. https://doi.org/10.1016/S0140-6736(00)03307-9
Zia Al Sabbah, AijazMansoor, UpendraKaul: Angiotensin receptor blockers-advantages of the new sartans. Journal of the Association of Physicians of India 2013; 61:464- 470.
Hussain A, Aqil M, Alam M.S, Khan M.R, Kapur P and Pillai K.K: A pharmacovigilance study of antihypertensive medicines at South Delhi hospital. Indian Journal of Pharmaceutical Sciences 2009; 71:338-341. https://doi.org/10.4103/0250-474X.56018
DegliEsposti E, Sturani A and Di Martino N: Long term persistence with anti-hypertensive drugs in new patients. Journal of Human Hypertension 2002; 16:439-444. https://doi.org/10.1038/sj.jhh.1001418
DegliEsposti L, DegliEsposti E and Valpiani G: A retrospective, population- based analysis of persistence with anti-hypertensive drug therapy in primary care practice in Italy. Clinical Therapeutics 2002; 24:1347- 1357. https://doi.org/10.1016/S0149-2918(02)80039-X
Monana M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R and Avorn J: The effects of initial drug choice and comorbidity on anti-hypertensive therapy compliance: results from a population-based study in the elderly. American Journal of Hypertension 1997; 10:697-704. https://doi.org/10.1016/S0895-7061(97)00056-3
Ross SD, Akhras KS, Zhang S, Rozinsky M and Nalysnyk L: Discontinuation of anti-hypertensive drugs due to adverse events: A systematic review and meta-analysis. Pharmacotherapy 2001; 21:940-953. https://doi.org/10.1592/phco.21.11.940.34520
Allhat Officers and co-ordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or Calcium channel blocker vs diuretic: The anti-hypertensive and lipid lowering treatment to prevent heart attack trial. The Journal of the American Medical Association.2002; 288:2981-2997. https://doi.org/10.1001/jama.288.23.2981
Lionel F, Baker: Triggering psoriasis: the role of infections and medications. Clinics in Dermatology 2007; 25:606- 615. https://doi.org/10.1016/j.clindermatol.2007.08.015
Jeffery. Martin: Hypertension Guidelines: Revisiting the JNC 7 recommendations. The Journal of Lancaster General Hospital 2008; 3:91-97.
Treatment with antihypertensive drugs. JSH Guidelines.Hypertension Research.2009; 32:33-39. https://doi.org/10.1038/hr.2008.5
William H. Frishman: Beta-adrenergic blockers, adverse effects and drug interactions. Journal of American Heart Association 1988; 11:II 21- II 29. https://doi.org/10.1161/01.HYP.11.3_Pt_2.II21
Joanna Lyford: Hypertension and beta-blockers may raise risk of psoriasis. The Pharmaceutical Journal 2014; 293.
Jain M, Jain A, Khare B, Jain DK, Khan R, Jain D. An Update on the Recent Emergence of Candida auris. Asian Journal of Dental and Health Sciences. 2022; 2(1):14-9. https://doi.org/10.22270/ajdhs.v2i1.11
Kormeili T, Lowe NJ, Yamauchi PS: Psoriasis: Immunopathogenesis and evolving immune-modulators and systemic therapies; U.S. Experiences. British Journal of Dermatology 2004; 151:3-15. https://doi.org/10.1111/j.1365-2133.2004.06009.x
Thao Nguyen, Jashin J Wu: Relationship between tumour necrosis factor- α inhibitors and cardiovascular disease in psoriasis: A review. The Permanente Journal 2014; 18:49- 54. https://doi.org/10.7812/TPP/13-092
Brauchli Y.B, Jick S.S, Curtin F and Meier C.R: Association between Beta blockers, other antihypertensive drugs and psoriasis: Population-based casecontrol study. British Journal of Dermatology 2008; 158:1299-1307. https://doi.org/10.1111/j.1365-2133.2008.08563.x
Jat D, Thakur N, Jain DK, Prasad S, Yadav R. Iris ensata Thunb: Review on Its Chemistry, Morphology, Ethno Medical Uses, Phytochemistry and Pharmacological Activities. Asian Journal of Dental and Health Sciences. 2022; 2(1):1-6. https://doi.org/10.22270/ajdhs.v2i1.9
Tsankov N, Kasandjieva J and Drenovska K: Drugs in exacerbation and provocation of psoriasis. Clinics in Dermatology 1998; 16:333-51. https://doi.org/10.1016/S0738-081X(98)00005-4
Naldi L, Parazzini F, Peli L, Chatenoud L and Cainelli T: Dietary factors and the risk of psoriasis. Results of an Italian case-control study.British Journal of Dermatology 1996; 134:101-106. https://doi.org/10.1046/j.1365-2133.1996.d01-734.x
Naldi L et al., Cigarette smoking, body mass index and stressful life events as risk factors for psoriasis: Results from an Italian case-control study. Journal of Investigative Dermatology 2005; 125:61-67. https://doi.org/10.1111/j.0022-202X.2005.23681.x
Steinkraus V, Steinfath M and Mensing H: Beta adrenergic blocking drugs and psoriasis. Journal of the American Academy of Dermatology 1992; 27:266-267. https://doi.org/10.1016/S0190-9622(08)80738-4
Halevy S, Livni E: Psoriasis and psoriasiform eruptions associated with propranolol - the role of an immunological mechanism. Archives of Dermatological Research 1991; 283:472-473. https://doi.org/10.1007/BF00371785
Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L and Halevy S: Drug exposure and Psoriasis vulgaris: casecontrol and case-crossover studies. ActaDermatoVenereologica 2005; 85:299-303. https://doi.org/10.1080/00015550510032823
Khatri S, Dhanoriya C, Jain DK. Zika virus (ZIKV) disease: past, present and future. Journal of Drug Delivery and Therapeutics. 2018; 8(6-s):320-7. https://doi.org/10.22270/jddt.v8i6-s.2076
Yadav R, Jha M, Prasad S, Jat D, Jain DK. Mayaro virus (MAYV) Disease: Past, present and future. J Pharm Biol Sci. 2022; 10(1):7-16.
Obrien M, Koo J: The mechanism of Lithium and Beta blocking agents in inducing and exacerbating psoriasis. Journal of Drugs in Dermatology 2006; 5:426-432.
Ockenfels HM et al., Tyrosine phosphorylation in psoriasis T-cells is modified by drugs that induce or improve psoriasis. Dermatology 1995; 191:217-225. https://doi.org/10.1159/000246549
Drs M Keefe, Hamlet N W and Rebecca E I Kerr: Psoriasis is a side effect of beta blockers. British Medical Journal 1987; 295: 1352. https://doi.org/10.1136/bmj.295.6609.1352-a
O'Brian M, Koo J: The mechanism of Lithium and Beta blocker agents in inducing an exacerbating psoriasis. Journal of Drugs in Dermatology 2006; 5:426-433.
Hypertension: Clinical Management of primary hypertension in adults. NICE Guidelines. 2011.
Tsankov N, Irena A and Kasandjieva J: Drug-induced psoriasis: Recognition and management. American Journal of Clinical Dermatology 2000; 1: 159-165. https://doi.org/10.2165/00128071-200001030-00003
Peter Trenkwalder: Anti-hypertensive treatment with calcium channel blockers: pharmacological pornography or useful intervention? Nephrology Dialysis Transplantation 2004; 19:17-20. https://doi.org/10.1093/ndt/gfg431
HarikrishnaMakani MD, Sripal Bangalore MD, MHA, Jorge Romero MD, Omar Wever-Pinzon MD, Franz H. Messerli MD: Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema. The American Journal of Medicine 2011; 124:128-135. https://doi.org/10.1016/j.amjmed.2010.08.007
Khatri S, Jain DK. Autism spectrum disorder (ASD): past, present and future. CIBTech Journal of Pharmaceutical Sciences. 2018; 7(4):1-25.
Livada R and Shiloah J: Calcium channel blocker-induced gingival enlargement. Journal of Human Hypertension 2014; 28:0-14. https://doi.org/10.1038/jhh.2013.47
Shetty AK, Shah HJ, Patil MA and Jhota KN: Idiopathic gingival enlargement and its management. Journal of Indian Society of Periodontology 2010; 14:263-265. https://doi.org/10.4103/0972-124X.76935
Vishakha Grover, AnoopKapoor and Marya CM: Amlodipine-induced gingival hyperplasia. Journal of Oral Health and Community Dentistry 2007; 1:19-22. https://doi.org/10.5005/johcd-1-1-19
Murat Sucu, Murat Yucc and VedatDavutoglu: Amlodipine-induced massive gingival hypertrophy. Canadian Family Physician 2011; 57:436-437.
Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ and Thomason JM: Prevalence of gingival overgrowth induced by calcium channel blockers: A community-based study. Journal of Periodontology 1999; 70:63-67 https://doi.org/10.1902/jop.1999.70.1.63
Pristant LM and Herman W: Calcium channel blocker induced gingival overgrowth. The Journal of Clinical Hypertension 2002; 4:310-311 https://doi.org/10.1111/j.1524-6175.2002.01095.x
Lucas RM, Howell LP, Wall BA: Nifedipine- induced gingival hyperplasia. A histochemical and ultrastructural study.Journal of Periodontology 1985; 56:211-215. https://doi.org/10.1902/jop.1985.56.4.211
Barclay S, Thomason JM, Idle JR, Seymour RA: The incidence and severity of Nifedipine induced gingival over growth. Journal of Clinical Periodontology 1992; 19:311- 314. https://doi.org/10.1111/j.1600-051X.1992.tb00650.x
Duncan MR, Berman B: Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblast by recombinant human interleukin-6. Journal of Investigative Dermatology 1991; 97:686-689. https://doi.org/10.1111/1523-1747.ep12483971
Gautam SP, Rai JP, Billshaiya U, Jain N, Vikram P, Jain DK. Formulation and evaluation of mouth dissolving tablet of loperamide. International Journal of Pharmaceutical Sciences and Research. 2013; 4(5):1782.
Patel AN, Rai JP, Jain DK, Banweer JI. Formulation, development and evaluation of cefaclor extended release matrix tablet. Int J Pharm Pharm Sci. 2012; 4(4):355-7.
Torpet LA, Kragelund C, Reibel J and Nauntofte B: Oral adverse drug reaction to cardiovascular drugs. Critical Reviews in Oral Biology and Medicine 2004; 15:28-46. https://doi.org/10.1177/154411130401500104
Katheryn P, Traues MD and James S. Edema: Diagnosis and Management. American Academy of Family Physicians 2013; 88:102-110.
Domenic A. Sica: Calcium channel-related peripheral oedema; can it be resolved? The Journal of Clinical Hypertension 2003; 5:291-295. https://doi.org/10.1111/j.1524-6175.2003.02402.x
Messerli FH and Groossman E: Pedal oedema-not all dihydropyridine calcium antagonist are created equal. American Journal of Hypertension 2002; 15:1019-1020. https://doi.org/10.1016/S0895-7061(02)03087-X
Sirker A, Missouris CG and Macgregor G: Dihydropyridine calcium channel blockers and peripheral side effects. Jounal of Human Hypertension 2001; 15:745- 746. https://doi.org/10.1038/sj.jhh.1001248
Rajeev Kumar, Ramji Sharma, KhemrajBairwa, Ram Kumar Roy, Arun Kumar and AtulBaruwa: Modern Development in ACE inhibitors. Der Pharmacia Lettre 2010; 2:388-419.
Pandey SP, Khan MA, Dhote V, Dhote K, Jain DK. Formulation development of sustained release matrix tablet containing metformin hydrochloride and study of various factors affecting dissolution rate. Sch Acad J Pharm. 2019; 8(3):57-73.
Jain P, Nair S, Jain N, Jain DK, Jain S. Formulation and evaluation of solid dispersion of lomefloxacin hydrochloride. Int J Res Pharm Sci 2012; 3(4):604-608.
Upendra Kaul, Aijaz Mansoor and Zia Al Sabbah: Angiotensin Receptor Blockers-Advantages of the New Sartans. Journal of the Association of Physicians of India 2013; 61:464- 470.
Philip BabatundeAdebayol and Olutayo Christopher Alebiosu: ACE-I induced Angioedema: A case report and Review of literature 2009; 2: 7181. https://doi.org/10.4076/1757-1626-2-7181
Sharabi Y, Illan R, Kamari Y, Cohen H, Nadler M, Grossman E and Messerli FH: Diuretic induced hyponatraemia in elderly hypertensive women. Journal of Human Hypertension 2002; 16:631-635. https://doi.org/10.1038/sj.jhh.1001458
Domenic A. Sica: Diuretics related side effects: development and treatment. The Journal of Clinical Hypertension 2004; 6:532-540. https://doi.org/10.1111/j.1524-6175.2004.03789.x
Lawrence R. Krakoff: Diuretics for hypertension. American Heart Association 2005; 112:127-129. https://doi.org/10.1161/CIRCULATIONAHA.105.570192
Patel NS, Jain DK, Nagar H, Patel A, Chandel HS. Evaluation of analgesic and antipyretic activity of Tridax procumbens leaves extract. RGUHS J Pharm Sci. 2011; 1(3):226-31. https://doi.org/10.5530/rjps.2011.3.9
Kyu Sig Hwang and Gheun-Ho Kim: Thiazide-induced hyponatremia. Electrolyte Blood Press 2010; 8:51-57. https://doi.org/10.5049/EBP.2010.8.1.51
Anil K. Mandal, Linda M. Hiebert: Is Diuretic-Induced Hyperglycemia Reversible and Inconsequential? Journal of Diabetes Research and Clinical Metabolism 2012; 1:1-4. https://doi.org/10.7243/2050-0866-1-4
Padwal R, Laupacis: A Antihypertensive therapy and incidence ot Type 2 diabetes. Diabetes Care 2004, 27:247- 255. https://doi.org/10.2337/diacare.27.1.247
Halderman JH, Elahi D, Anderson DK, Raizes GS, Tobin JD, Shocken D, Andres R: Prevention of glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983, 32:106-111. https://doi.org/10.2337/diabetes.32.2.106
Published
How to Cite
Issue
Section
Citations
Copyright (c) 2022 Devraj Rajak, Deepali Sahu, Anushree Jain, Rubeena Khan, Basant Khare, Prateek Kumar Jain, Bhupendra Singh Thakur
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.